In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beckman Coulter's Play for High Growth

Executive Summary

With the Coulter integration successful, Beckman Coulter looks for high-growth opportunities outside of its traditional businesses. Beckman, through internal efforts in its life sciences business and a series of small alliances, is making a play in genomics and proteomics. In addition to building up near-term revenues, the aim is to find new "content" in the form of assays for its clinical business.

You may also be interested in...

Do Dx-Life Science Synergies Exist? Beckman Says 'You Bet They Do'

Life sciences and clinical diagnostics seem to have a lot in common, but their customer needs, margins and product life cycles differ significantly. Beckman Coulter, one of the few large diagnostics companies with significant life science commitments, argues vociferously in favor of the strategic value of leveraging both businesses, despite many difficulties. Its MHC tetramer program is a prime example of its strategy.

Post Abbott Consent Decree; A Changed World for Immunoassay Vendors

Abbott's prolonged problems with the FDA in the immunoassaay diagnostics market obviously created opportunities for competitors. Critics say, however, their response has been slow and none are able to step directly into Abbott's shoes. Companies initially viewed the situation as a short-term opportunity, but now they may become more aggressive as Abbott's grip on the market weakens.

Big Diagnostics Companies See the Genomics Light

Until now, large diagnostics companies have been slow to get involved in the industry's biggest paradigm shift in a decade: the move to molecular markers that will help make diagnostics part of the treatment process. At this year's AACC, the small companies leading the way in this field were beginning to make their presence felt. And the big companies, J&J, Roche, Abbott, Beckman, were starting to talk about their own programs in the field. But they're moving slowly in a fast-moving field, and thus are vulnerable to new competitors.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts